Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to people with chronic neutropenic disorders and WHIM syndrome.
Our deep understanding of the biology of the CXCR4 pathway has enabled us to advance our lead candidate, mavorixafor, an orally available antagonist of the CXCR4 receptor, into clinical development. In clinical trials to date, mavorixafor has demonstrated the ability to improve the mobilization of neutrophils, lymphocytes, and monocytes into the blood stream in people with moderate to severe chronic neutropenic disorders, WHIM syndrome, and certain cancers.
We believe that successfully developing mavorixafor and providing a new therapeutic option to people with chronic neutropenic disorders has the potential to revolutionize the treatment landscape, which is currently only served by injectable therapies that have been associated with high-burden side effects.
Unparalleled Expertise in CXCR4 and Immune System Biology
In addition to our headquarters in Boston, Massachusetts, we have established a research center of excellence in Vienna, Austria. Here, our scientists not only focus on new drug discovery and on better understanding immune system dysfunction and the role of the CXCR4/CXCL12 axis in maintaining healthy immunity, but also on further studying the genetic causes of certain chronic neutropenic disorders and the mechanism of mavorixafor.